These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 25886314)

  • 1. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting autophagy to sensitive glioma to temozolomide treatment.
    Yan Y; Xu Z; Dai S; Qian L; Sun L; Gong Z
    J Exp Clin Cancer Res; 2016 Feb; 35():23. PubMed ID: 26830677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceramide Is Involved in Temozolomide Resistance in Human Glioblastoma U87MG Overexpressing EGFR.
    Bassi R; Dei Cas M; Tringali C; Compostella F; Paroni R; Giussani P
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
    Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
    Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A co-culture model with brain tumor-specific bioluminescence demonstrates astrocyte-induced drug resistance in glioblastoma.
    Yang N; Yan T; Zhu H; Liang X; Leiss L; Sakariassen PØ; Skaftnesmo KO; Huang B; Costea DE; Enger PØ; Li X; Wang J
    J Transl Med; 2014 Oct; 12():278. PubMed ID: 25280402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ProNGF Expression and Targeting in Glioblastoma Multiforme.
    Marsland M; Dowdell A; Faulkner S; Jobling P; Rush RA; Gedye C; Lynam J; Griffin CP; Baker M; Marsland J; Jiang CC; Hondermarck H
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide resistance mechanisms: unveiling the role of translesion DNA polymerase kappa in glioblastoma spheroids in vitro.
    Ribeiro DL; Latancia MT; de Souza I; Ariwoola AA; Mendes D; Rocha CRR; Lengert AVH; Menck CFM
    Biosci Rep; 2024 May; 44(5):. PubMed ID: 38717250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma.
    Wang F; Zhu Y; Wanggou S; Lin D; Su J; Li X; Tao E
    Cancer Lett; 2024 Jun; 592():216920. PubMed ID: 38679408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
    Nam Y; Koo H; Yang Y; Shin S; Zhu Z; Kim D; Cho HJ; Mu Q; Choi SW; Sa JK; Seo YJ; Kim Y; Lee K; Oh JW; Kwon YJ; Park WY; Kong DS; Seol HJ; Lee JI; Park CK; Lee HW; Yoon Y; Wang J
    Genome Med; 2023 Mar; 15(1):16. PubMed ID: 36915208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells.
    Dong F; Eibach M; Bartsch JW; Dolga AM; Schlomann U; Conrad C; Schieber S; Schilling O; Biniossek ML; Culmsee C; Strik H; Koller G; Carl B; Nimsky C
    Neuro Oncol; 2015 Nov; 17(11):1474-85. PubMed ID: 25825051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line.
    Barciszewska AM; Belter A; Gawrońska I; Giel-Pietraszuk M; Naskręt-Barciszewska MZ
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.
    Blomquist MR; Eghlimi R; Beniwal A; Grief D; Nascari DG; Inge L; Sereduk CP; Tuncali S; Roos A; Inforzato H; Sharma R; Pirrotte P; Mehta S; Fortin Ensign SP; Loftus JC; Tran NL
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
    Kushal S; Wang W; Vaikari VP; Kota R; Chen K; Yeh TS; Jhaveri N; Groshen SL; Olenyuk BZ; Chen TC; Hofman FM; Shih JC
    Oncotarget; 2016 Mar; 7(12):13842-53. PubMed ID: 26871599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma.
    Budhiraja S; McManus G; Baisiwala S; Perrault EN; Cho S; Saathoff M; Chen L; Park CH; Kazi HA; Dmello C; Lin P; James CD; Sonabend AM; Heiland DH; Ahmed AU
    Neuro Oncol; 2024 Aug; 26(8):1421-1437. PubMed ID: 38506351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide.
    Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J
    Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
    Den RB; Kamrava M; Sheng Z; Werner-Wasik M; Dougherty E; Marinucchi M; Lawrence YR; Hegarty S; Hyslop T; Andrews DW; Glass J; Friedman DP; Green MR; Camphausen K; Dicker AP
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):321-8. PubMed ID: 22687197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased eukaryotic initiation factors expression upon temozolomide treatment-potential novel implications for eIFs in glioma therapy.
    Krassnig S; Leber SL; Orthmann A; Golob-Schwarzl N; Huber HJ; Wohlrab C; Skofler C; Pennauer M; Raicht A; Birkl-Toeglhofer AM; Naumann M; Mahdy-Ali K; von Campe G; Leoni M; Alcaniz J; Hoffmann J; Wälchli T; Weis S; Benesch M; Haybaeck J
    J Neurooncol; 2023 Oct; 165(1):91-100. PubMed ID: 37907716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
    Sun S; Wong TS; Zhang XQ; Pu JK; Lee NP; Day PJ; Ng GK; Lui WM; Leung GK
    J Neurooncol; 2012 Mar; 107(1):89-100. PubMed ID: 21979894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
    Feng SW; Wu ZS; Chiu YL; Huang SM
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells.
    Chernov AN; Kim AV; Skliar SS; Fedorov EV; Tsapieva AN; Filatenkova TA; Chutko AL; Matsko MV; Galimova ES; Shamova OV
    Cancer Chemother Pharmacol; 2024 May; 93(5):455-469. PubMed ID: 38280033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.